CHENGDU, China, April 6, 2025 /PRNewswire/ -- Keymed Biosciences Inc. (HKEX: 02162) ("Keymed" or the "Company") today announced that the prestigious medical journal Nature Medicine has published the ...

Galux, founded by Professor Seok Cha-ok of Seoul National University, successfully designed completely new proteins using AI. Galux has designed six types of antibody proteins that can be used for ...

Pioneering AI technology successfully designs antibodies de novo for six therapeutic targets, including one without an experimentally resolved structure SEOUL, South Korea, March 17, 2025 /PRNewswire/ ...

With over 25 years of expertise in the field, Galux is pioneering AI-powered protein design with its proprietary platform, GaluxDesign, which enables precise de novo protein design and engineering.